RESULTS: In this study, a murine model of non-alcoholic steatohepatitis (NASH) was established by feeding C57BL/6 female mice a high-fat diet for 12 weeks. Kaempferol (Kae) was investigated for its ability to modulate systemic inflammatory responses and lipid metabolism in this model (20 mg/kg per day). Notably, Kae significantly reduced the expression of NLRP3-ASC/TMS1-Caspase 3, a crucial mediator of liver tissue inflammation. Additionally, in a HepG2 cell model induced with palmitic acid/oleic acid (PA/OA) to mimic NASH conditions, Kae demonstrated the capacity to decrease lipid droplet accumulation and downregulate the expression of NLRP3-ASC/TMS1-Caspase 3 (20 µM and the final concentration to 20 nM). These findings suggest that Kae may hold therapeutic potential in the treatment of NASH by targeting inflammatory and metabolic pathways.
CONCLUSIONS: These findings suggest that kaempferol holds potential as a promising therapeutic intervention for ameliorating non-alcoholic fatty liver disease (NAFLD).
结果:在这项研究中,通过高脂饮食喂养C57BL/6雌性小鼠12周,建立了非酒精性脂肪性肝炎(NASH)的小鼠模型。研究山奈酚(Kae)在该模型中调节全身炎症反应和脂质代谢的能力(20mg/kg/天)。值得注意的是,Kae显着降低了NLRP3-ASC/TMS1-Caspase3的表达,后者是肝组织炎症的关键介质。此外,在用棕榈酸/油酸(PA/OA)诱导的HepG2细胞模型中模拟NASH条件,Kae表现出减少脂滴积累和下调NLRP3-ASC/TMS1-Caspase3表达的能力(20μM,终浓度为20nM)。这些发现表明Kae可能通过靶向炎症和代谢途径在NASH的治疗中具有治疗潜力。
结论:这些研究结果表明,山奈酚作为改善非酒精性脂肪性肝病(NAFLD)的一种有希望的治疗干预措施具有潜力。